Download PDF
Aktuelle Kardiologie 2012; 1(04/05): 295-298
DOI: 10.1055/s-0032-1324824
Übersichtsarbeit
Georg Thieme Verlag KG Stuttgart · New York

Aktuelle medikamentöse Therapie der chronischen Herzinsuffizienz

Current Pharmacological Treatment of Chronic Heart Failure
R. Steinacher
1   Universitätsklinik für Innere Medizin II, Paracelsus Universität Salzburg
,
D. Rottländer
1   Universitätsklinik für Innere Medizin II, Paracelsus Universität Salzburg
,
U. C. Hoppe
1   Universitätsklinik für Innere Medizin II, Paracelsus Universität Salzburg
› Author Affiliations
Further Information

Publication History

Publication Date:
16 October 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

ACE-Hemmer (oder alternativ ARBs) und Betablocker bleiben die Basistherapie der systolischen Herzinsuffizienz und müssen aufdosiert werden. Der Indikationsbereich der Aldosteronantagonisten wurde auf das NYHA-Stadium II ausgeweitet. Ivabradin stellt eine zusätzliche Therapieoption dar, wenn trotz aufdosiertem Betablocker die Herzfrequenz im Sinusrhythmus über 70/min liegt. Für Statine und die orale Antikoagulation ergibt sich die Indikation allenfalls aus den Komorbiditäten, nicht aus der Herzinsuffizienz selbst. Zahlreiche Medikamente sollten bei der systolischen Herzinsuffizienz gemieden werden. Diuretika dienen bei Herzinsuffizienz unabhängig von der Pumpfunktion zur Symptomlinderung bei Flüssigkeitsretention. Für die Herzinsuffizienz mit erhaltener Pumpfunktion besteht darüber hinaus vorrangig die Empfehlung zur Blutdruckeinstellung.

Abstract

ACE-Inhibitors (or alternatively ARBs) and beta-blockers remain the first line treatment in systolic heart failure and should be up-titrated to evidence-based target doses. Recommendations for the use of mineralocorticoid receptor antagonists have been extended to all patients in NYHA class II–IV. Ivabradine should be considered in patients in sinus rhythm, EF < 35 % and a heart rate > 70 beats/min despite maximum dosage of betablockers. Statins and oral anticoagulation in patients with sinus rhythm show no benefit for heart failure. Various drugs may cause worsening of heart failure and thus should be avoided due to safety concerns. Diuretics serve for symptom relieve in heart failure with fluid retention independent of the pump function. For heart failure with preserved ejection fraction in addition blood pressure control is of particular relevance.

Schlüsselwörter

Herzinsuffizienz - medikamentöse Therapie - Aldosteronantagonist - Ivabradin

Key words

heart failure - pharmacological therapy - aldosteron antagonist - ivabradine
 

  • Literatur

  • 1 Paulus WJ, Tschope C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550
    CrossrefPubMedGoogle Scholar
  • 2 Jhund PS, Macintyre K, Simpson CR et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009; 119: 515-523
    CrossrefPubMedGoogle Scholar
  • 3 Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269
    CrossrefPubMedGoogle Scholar
  • 4 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847
    CrossrefPubMedGoogle Scholar
  • 5 Studer R, Reinecke H, Muller B et al. Increased angiotensin-I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest 1994; 94: 301-310
    CrossrefPubMedGoogle Scholar
  • 6 Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805
    CrossrefPubMedGoogle Scholar
  • 7 Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697
    CrossrefPubMedGoogle Scholar
  • 8 Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
    Google Scholar
  • 9 Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
    Google Scholar
  • 10 Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885
    CrossrefPubMedGoogle Scholar
  • 11 Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261
    CrossrefPubMedGoogle Scholar
  • 12 Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239
    CrossrefPubMedGoogle Scholar
  • 13 Homma S, Thompson JL, Pullicino PM et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366: 1859-1869
    CrossrefPubMedGoogle Scholar
  • 14 Komajda M, McMurray JJ, Beck-Nielsen H et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31: 824-831
    CrossrefPubMedGoogle Scholar
  • 15 Connolly SJ, Camm AJ, Halperin JL et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011; 365: 2268-2276
    CrossrefPubMedGoogle Scholar